1–3 of 3 results for optogenetics
BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)
Michael A. Singer, MD
Annual Meeting Talks
2024
BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)
Updates from the Field
Episode 207: January 2020 Retinal Physician Preview: EHR Integration, Swept-Source OCTA, Intraoperative OCT, Optogenetics
Jayanth Sridhar, MD
Member Podcasts
2020